Sinai Health: How Blood-Based IBD Biomarkers Are Redefining the Future of Precision Medicine in IBD
Recent research from Sinai Health has revealed a compelling breakthrough in inflammatory bowel disease (IBD): a simple blood test may be able to predict Crohn’s disease years before symptoms appear. By identifying early immune responses to bacterial flagellin in genetically at-risk individuals, researchers are opening the door to earlier intervention - before irreversible inflammation and tissue damage take hold.
This discovery is about far more than early diagnosis. It signals a shift toward a future where biomarkers enable prevention, smarter clinical trial design, and truly proactive precision medicine in IBD.
As our understanding of immune signalling, microbial interactions, and patient heterogeneity deepens, the field is moving beyond one-size-fits-all therapies and toward durable, patient-specific outcomes in both Crohn’s disease and ulcerative colitis.
These advances sit at the heart of the 4th Precision Medicine in Inflammatory Bowel Disease Summit, which brings together leaders across biomarker discovery, translational science, and therapeutic development.
The goal is clear: move the field beyond partial responses and unlock higher efficacy ceilings through precision-driven strategies.
This year’s summit agenda places a strong emphasis on how biomarkers and multiomic profiling are reshaping IBD research and development, from early discovery to late-stage clinical execution.
Attendees will explore how biomarker-driven insights are taking center stage across the IBD pipeline. Find out more in our 2026 Precision Medicine in IBD brochure and register to be part of a program connecting biomarker discovery with combination therapy development—helping define the future of precision medicine in IBD.
Explore the Agenda
Discover cutting-edge sessions on AI, biomarkers, and combination therapies redefining IBD precision medicine.
Partner With Us
Connect with senior biopharma leaders seeking innovative tools, models, and data solutions to advance IBD pipelines.
Join Biopharma Experts
Network with industry pioneers shaping the next generation of personalized Crohn’s and Colitis treatments.